AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:03 12/12/2025 GMT			5-day change	1st Jan Change
13,444.00 ^GBX	-1.12%		-1.09%	+28.43%

02:27pm	European health regulator recommends approval for GSK's twice-yearly asthma drug	RE
12:06pm	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE

Baxdrostat new drug application accepted under FDA priority review in the US for patients with hard-to-control hypertension

Published on 12/02/2025 at 02:43 pm GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AstraZeneca PLC

02:27pm	European health regulator recommends approval for GSK's twice-yearly asthma drug	RE
12:06pm	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
05:48am	Swedish Stocks in North America – AstraZeneca Drops 0.8 Percent	FW
12-11	Outgoing GSK CEO Emma Walmsley declares US best place to invest	AN
12-10	Syneron Tech announced that it has received $100 million in funding from a group of investors	CI
12-10	Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial	RE
12-10	Banks support FTSE 100 ahead of Fed decision	RE
12-09	Astrazeneca, Daiichi Sankyo Begin Phase 3 Trial of Enhertu Combination in Ovarian Cancer	MT
12-09	Destiny-Ovarian01 Phase 3 Trial of Enhertu Initiated as First-Line Maintenance Therapy in Patients with Her2 Expressing Advanced Ovarian Cancer	CI
12-09	Century Therapeutics, Inc. Announces Board and Committee Appointments	CI
12-09	Rusta report winner on the Stockholm Stock Exchange, OMXS30 index down 0.5 percent	FW
12-09	US FDA launches fresh safety scrutiny of approved RSV therapies for infants	RE
12-09	U.S. FDA officials inform Merck, Sanofi and AstraZeneca RSV antibody therapies would receive fresh safety scrutiny - sources familiar with the situation	RE
12-08	Pillar Biosciences and AstraZeneca expand liquid biopsy access partnership to China	RE
12-08	Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China	CI
12-08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-08	Hutchmed drugs stay on NRDL; Tazverik added to new insurance list	AN
12-08	JPMorgan cuts M&G, UBS cuts Trainline	AN
12-08	C WorldWide Sweden Down 0.8 Percent in November, Weighed Down by Storytel, Invisio, and Lime Technologies	FW
12-08	ASTRAZENECA : JP Morgan remains its Buy rating	ZD
12-08	The end of the "European discount" for TotalEnergies?
12-05	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
12-05	Swedish stocks in North America - Ericsson fell 1.0 percent	FW
12-04	Salesforce?S Agentforce Life Sciences Selected by Astrazeneca as Its Unified Global Platform to Help Transform Customer Engagement	CI
12-04	ASTRAZENECA : Bernstein remains its Buy rating	ZD

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

12-15 - Scotiabank Rare Disease Fireside Chat Conference

More about the company